Cite
HARVARD Citation
Andersen, M. et al. (2020). Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma. Acta oncologica. pp. 1547-1551. [Online].